GUTS — Fractyl Health, Inc. Common Stock

Summary of Fractyl Health Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Research and Development Expenses: $16.5 million for Q4 2025, down from $20.3 million in Q4 2024, attributed to strategic reprioritization and reduced personnel costs.
• SG&A Expenses: Increased to $6.8 million from $4.9 million year-over-year, primarily due to underwriter commissions from financing.
• Net Loss: Reported at $43.7 million, up from $25 million in Q4 2024. The increase included a non-cash accounting change of $20.2 million related to warrant liabilities.
• Adjusted EBITDA: Negative $21.2 million, slightly improved from negative $22.1 million in the prior year.
• Cash Position: Approximately $81.5 million as of December 31, 2025, with additional $4.1 million from warrant exercises in January 2026, expected to fund operations into early 2027.

2. Strategic Updates and Business Highlights

• Revita Development: The company is focusing on Revita, a procedure designed to maintain weight loss after discontinuation of GLP-1 therapy. Positive feedback from the FDA regarding the De Novo classification request was received, indicating a potential Class II device classification.
• Clinical Data: The REMAIN-1 pivotal study has shown a strong dose-response relationship between ablation length and weight maintenance, with a mean ablation length of over 16 centimeters in the pivotal cohort.
• Commercial Strategy: Fractyl plans to file a Category III CPT code application in summer 2026, with reimbursement pathways being established to support hospital economics for the Revita procedure.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Q2 2026: 1-year REVEAL-1 open-label data and regulatory feedback on RJVA-001.
  • Q3 2026: 1-year REMAIN-1 Midpoint Cohort randomized data.
  • Early Q4 2026: Top line 6-month data from the REMAIN-1 pivotal study.
  • Late Q4 2026: Potential De Novo marketing application submission for Revita.
• Market Opportunity: There is a growing population on GLP-1 drugs, with expectations that over 30 million users will emerge in the coming years, increasing the demand for durable weight maintenance solutions.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The significant rise in net loss raises concerns about the company's financial health, despite the non-cash nature of a portion of the loss.
• Clinical Data Variability: Initial clinical data showed variability in treatment efficacy based on ablation length, which could impact the perception of Revita's effectiveness.
• Regulatory Risks: While FDA feedback has been favorable, the success of the De Novo submission and subsequent commercialization remains contingent on meeting regulatory standards.

5. Notable Q&A Insights

• Ablation Length Training: Physicians are trained to achieve at least 10 centimeters of ablation, with a target of over 16 centimeters for optimal efficacy. The training process is relatively quick, taking about 3-4 cases.
• Regulatory Submission Process: The De Novo submission will consist of multiple packages, including clinical data, and the efficacy threshold differs from PMA submissions.
• Payer Discussions: The company plans to initiate discussions with payers late this year, leveraging comprehensive clinical data expected to be available by early Q4 2026.

Overall, Fractyl Health is positioning itself strategically for the commercialization of Revita, with a focus on clinical efficacy and regulatory compliance, despite facing financial losses and the inherent risks of clinical trials.